{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-033612","form_type":"8-K","ticker":"ESPR","cik":"0001434868","company_name":"Esperion Therapeutics, Inc.","filed_at":"2025-07-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.987908+00:00","generated_at":"2026-05-18T09:56:38.356389+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Esperion appoints Craig Thompson to Board of Directors; board now has eight members","bullets":["Craig Thompson appointed to Esperion Board as independent Class II director, effective July 1, 2025.","Board expands from seven to eight members; Thompson will serve on Compliance, Nominating/Gov., and Commercial Committees.","Thompson is CEO of Cerevance and has held leadership roles at Neurana, Anthera, Tetraphase, Trius, Pfizer, and Merck.","He led commercial development of torcetrapib/atorvastatin at Pfizer and was involved in Trius' $700M+ acquisition by Cubist.","Thompson holds a BComm from McMaster University and an MBA from the University of Notre Dame."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-033612","json":"https://secwatch.observer/filing/0001628280-25-033612.json","markdown":"https://secwatch.observer/filing/0001628280-25-033612.md","text":"https://secwatch.observer/filing/0001628280-25-033612.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000162828025033612/0001628280-25-033612-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000162828025033612/espr-20250701.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:56:38.356389+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}